Comparative safety of futibatinib vs pemigatinib in metastatic cholangiocarcinoma: FAERS-based analysis
Department
Oncology and Hematology
Document Type
Conference Proceeding
Publication Title
Journal of Clinical Oncology
Conference Name
American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Conference Date
2026-01-08 - 2026-01-10
First Page
512
DOI
10.1200/JCO.2026.44.2_suppl.512
Volume
44
Issue
2_suppl
Publication Date
1-12-2026
Recommended Citation
Buradkar, A., Malipeddi, D., Shah, Z., Al-Alwan, A., Patel, R., Iyer, R., & Thanikachalam, K. (2026). Comparative safety of futibatinib vs pemigatinib in metastatic cholangiocarcinoma: FAERS-based analysis. Journal of Clinical Oncology, 44 (2_suppl), 512. https://doi.org/10.1200/JCO.2026.44.2_suppl.512
COinS